APVO - Buy Aptevo Therapeutics Before Their Q2 Results
While there is not much in terms of headline news for Aptevo Therapeutics (APVO) as of late, there are many things happening "under the hood" that might warrant investor's attention. Because depending on how things proceed for the company, the profits to be had for investors might be extraordinary.
?s per the previous quarter, revenue for the company's Hemophilia B drug IXINITY increased by 73% Y/Y to $7M. This is very important for 2 reasons.
First of all the market was modeling $6M in revenue, which means the adoption of the drug